Research Article
Revolutionary Integration of AI in Drug Development: A Comprehensive Analysis
@INPROCEEDINGS{10.4108/eai.12-1-2024.2347179, author={Jiayu Fang and Haoyu Bian and Jingyan Wu and Hanyu Pei and Pu Du}, title={Revolutionary Integration of AI in Drug Development: A Comprehensive Analysis}, proceedings={Proceedings of the 3rd International Conference on Big Data Economy and Digital Management, BDEDM 2024, January 12--14, 2024, Ningbo, China}, publisher={EAI}, proceedings_a={BDEDM}, year={2024}, month={6}, keywords={artificial intelligence in drug development ai-assisted diagnostics multi-omics data analysis advancement in personalized medicine technological shift in the pharmaceutical industry}, doi={10.4108/eai.12-1-2024.2347179} }- Jiayu Fang
Haoyu Bian
Jingyan Wu
Hanyu Pei
Pu Du
Year: 2024
Revolutionary Integration of AI in Drug Development: A Comprehensive Analysis
BDEDM
EAI
DOI: 10.4108/eai.12-1-2024.2347179
Abstract
Artificial Intelligence (AI) is revolutionizing drug development, introducing significant advancements in diagnostics, drug information analysis, and multi-omics data interpretation. AI's role in diagnostics is streamlining drug information collection, leading to enhanced decision-making and the development of more personalized medications. In drug design, AI's ability to analyze vast biological datasets is accelerating the discovery of new drug targets and pathways, making the research process more efficient and cost-effective. While the integration of AI in pharmaceutical research presents challenges such as data quality and ethical considerations, its potential for transforming drug development is immense. This technological shift promises a new era in healthcare, with AI-driven innovations paving the way for breakthroughs in disease treatment and patient care.
